GH Research PLC (NASDAQ:GHRS) Sees Large Increase in Short Interest

GH Research PLC (NASDAQ:GHRS) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 1,320,000 shares, a growth of 12.8% from the May 31st total of 1,170,000 shares. Approximately 4.3% of the company’s shares are sold short. Based on an average daily trading volume, of 73,500 shares, the days-to-cover ratio is presently 18.0 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. PEAK6 Investments LLC boosted its position in shares of GH Research by 72.9% during the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after acquiring an additional 16,991 shares in the last quarter. RTW Investments LP boosted its position in shares of GH Research by 53.4% during the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after acquiring an additional 1,158,172 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of GH Research by 14.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock worth $617,000 after acquiring an additional 13,579 shares in the last quarter. AdvisorShares Investments LLC boosted its position in shares of GH Research by 4.3% during the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after acquiring an additional 1,977 shares in the last quarter. Finally, BVF Inc. IL boosted its position in shares of GH Research by 12.1% during the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock worth $60,321,000 after acquiring an additional 1,125,000 shares in the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GHRS has been the topic of several research analyst reports. Canaccord Genuity Group boosted their price objective on GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a report on Monday, May 6th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Tuesday, May 7th.

GH Research Trading Up 1.2 %

GHRS traded up $0.14 on Wednesday, hitting $12.05. 37,787 shares of the company were exchanged, compared to its average volume of 103,273. GH Research has a twelve month low of $5.05 and a twelve month high of $14.99. The company has a market cap of $626.96 million, a price-to-earnings ratio of -19.21 and a beta of 0.86. The firm has a 50-day moving average price of $12.32 and a two-hundred day moving average price of $9.69.

GH Research (NASDAQ:GHRS) last released its earnings results on Friday, May 3rd. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. Equities analysts expect that GH Research will post -0.84 EPS for the current year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).